Efficacy and safety of single-agent pertuzumab (rhuMAb 2C4), a human epidermal growth factor receptor dimerization inhibitor, in castration-resistant prostate cancer after progression from taxane-based therapy

Journal of Clinical Oncology

Volumn 25, Issue 6, 2007, Pages 675-681

  Agus, David B ^a   Sweeney, Christopher J ^a   Morris, Michael J ^a   Mendelson, David S ^a   McNeel, Douglas G ^a   Ahmann, Frederick R ^a   Wang, Jin ^a   Derynck, Mika K ^a   Ng, Kimmie ^a   Lyons, Benjamin ^a   Allison, David E ^a   Kattan, Michael W ^a   Scher, Howard I ^a  

^a GENENTECH INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; PERTUZUMAB; PROSTATE SPECIFIC ANTIGEN; TAXANE DERIVATIVE; BRIDGED COMPOUND; EPIDERMAL GROWTH FACTOR RECEPTOR 2; MONOCLONAL ANTIBODY; TAXANE; TAXOID; UNCLASSIFIED DRUG;

ADULT; ANOREXIA; ARTHRALGIA; ARTICLE; ASTHENIA; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER SURVIVAL; CARDIOTOXICITY; CASTRATION; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DIMERIZATION; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; DYSURIA; FATIGUE; FEVER; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; HYPESTHESIA; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MUCOSA INFLAMMATION; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA; NECK PAIN; NOMOGRAM; PAIN; PATIENT ASSESSMENT; PERIPHERAL EDEMA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; RETROSPECTIVE STUDY; SIDE EFFECT; SURVIVAL TIME; TREATMENT RESPONSE; UPPER RESPIRATORY TRACT INFECTION; VALIDATION PROCESS; AGED; DISEASE COURSE; DOSE RESPONSE; DRUG ADMINISTRATION; DRUG ANTAGONISM; DRUG RESISTANCE; MIDDLE AGED; MORTALITY; ORCHIECTOMY; PATHOLOGY; PROBABILITY; PROSTATE TUMOR; RISK ASSESSMENT; SINGLE BLIND PROCEDURE; SURVIVAL; TREATMENT OUTCOME; TUMOR RECURRENCE;

AGED; ANTIBODIES, MONOCLONAL; BRIDGED COMPOUNDS; DISEASE PROGRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, NEOPLASM; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; ORCHIECTOMY; PROBABILITY; PROGNOSIS; PROSTATIC NEOPLASMS; RECEPTOR, ERBB-2; RISK ASSESSMENT; SINGLE-BLIND METHOD; SURVIVAL ANALYSIS; TAXOIDS; TREATMENT OUTCOME;

EID: 33947594043     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2006.07.0649     Document Type: Article

References (38)

1. Tannock IF, de Wit R, Berry WR, et al: Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351:1502-1512, 2004
2. Petrylak DP, Tangen CM, Hussain MH, et al: Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 351:1513-1520, 2004
3. Beekman KW, Fleming MT, Scher HI, et al: Second-line chemotherapy for prostate cancer: Patient characteristics and survival. Clin Prostate Cancer 4:86-90, 2005
4. Burgess AW, Cho HS, Eigenbrot C, et al: An open-and-shut case? Recent insights into the activation of EGF/ErbB receptors. Mol Cell 12:541-552, 2003
5. Yarden Y, Sliwkowski MX: Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2:127-137, 2001
6. Holbro T, Civenni G, Hynes NE: The ErbB receptors and their role in cancer progression. Exp Cell Res 284:299-310, 2003
7. Suzuki H, Ueda T, Ichikawa T, et al: Androgen receptor involvement in the progression of prostate cancer. Endocr Relat Cancer 10:209-216, 2003
8. El Sheikh SS, Domin J, Abel P, et al: Phosphorylation of both EGFR and ErbB2 is a reliable predictor of prostate cancer cell proliferation in response to EGF. Neoplasia 6:846-853, 2004
9. Scher HI, Buchanan G, Gerald W, et al: Targeting the androgen receptor: Improving outcomes for castration-resistant prostate cancer. Endocr Relat Cancer 11:459-476, 2004
10. Pinkas-Kramarski R, Soussan L, Waterman H, et al: Diversification of Neu differentiation factor and epidermal growth factor signaling by combinatorial receptor interactions. Embo J 15:2452-2467, 1996
11. Alimandi M, Romano A, Curia MC, et al: Cooperative signaling of ErbB3 and ErbB2 in neoplastic transformation and human mammary carcinomas. Oncogene 10:1813-1821, 1995
12. Wallasch C, Weiss FU, Niederfellner G, et al: Heregulin-dependent regulation of HER2/neu oncogenic signaling by heterodimerization with HER3. Embo J 14:4267-4275, 1995
13. Sliwkowski MX: Ready to partner. Nat Struct Biol 10:158-159, 2003
14. Signoretti S, Montironi R, Manola J, et al: Her-2-neu expression and progression toward androgen independence in human prostate cancer. J Natl Cancer Inst 92:1918-1925, 2000
15. Craft N, Shostak Y, Carey M, et al: A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase. Nat Med 5:280-285, 1999
16. Scher HI, Sarkis A, Reuter V, et al: Changing pattern of expression of the epidermal growth factor receptor and transforming growth factor alpha in the progression of prostatic neoplasms. Clin Cancer Res 1:545-550, 1995
17. Agus DB, Akita RW, Fox WD, et al: Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth. Cancer Cell 2:127-137, 2002
18. Morris MJ, Reuter VE, Kelly WK, et al: HER-2 profiling and targeting in prostate carcinoma. Cancer 94:980-986, 2002
19. Mellinghoff IK, Tran C, Sawyers CL: Growth inhibitory effects of the dual ErbB1/ErbB2 tyrosine kinase inhibitor PKI-166 on human prostate cancer xenografts. Cancer Res 62:5254-5259, 2002
20. Mellinghoff IK, Vivanco I, Kwon A, et al: HER2/neu kinase-dependent modulation of androgen receptor function through effects on DNA binding and stability. Cancer Cell 6:517-527, 2004
21. Gregory CW, Whang YE, McCall W, et al: Heregulin-induced activation of HER2 and HER3 increases androgen receptor transactivation and CWR-R1 human recurrent prostate cancer cell growth. Clin Cancer Res 11:1704-1712, 2005
22. Franklin MC, Carey KD, Vajdos FF, et al: Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex. Cancer Cell 5:317-328, 2004
23. Malik MA, Totpal K, Balter I, et al: Dose-response studies of recombinant humanized monoclonal antibody 2C4 in tumor xenograft models. Proc Am Assoc Cancer Res 44:150, 2003 (abstr 773)
24. Agus DB, Gordon MS, Taylor C, et al: Phase I clinical study of pertuzumab, a novel HER dimerization inhibitor, in patients with advanced cancer. J Clin Oncol 23:2534-2543, 2005
25. Blackledge G: Growth factor receptor tyrosine kinase inhibitors: Clinical development and potential for prostate cancer therapy. J Urol 170:S77-S83, 2003
26. Smaletz O, Scher HI, Small EJ, et al: Nomogram for overall survival of patients with progressive metastatic prostate cancer after castration. J Clin Oncol 20:3972-3982, 2002
27. Bubley GJ, Carducci M, Dahut W, et al: Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: Recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol 17:3461-3467, 1999
28. Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216, 2000
29. Negro A, Brar BK, Lee KF: Essential roles of Her2/ErbB2 in cardiac development and function. Recent Prog Horm Res 59:1-12, 2004
30. Simon R: Optimal two-stage designs for phase II clinical trials. Control Clin Trials 10:1-10, 1989
31. Ghali WA, Quan H, Brant R, et al: Comparison of 2 methods for calculating adjusted survival curves from proportional hazards models. JAMA 286:1494-1497, 2001
32. Scher HI, Morris MJ, Kelly WK, et al: Prostate cancer clinical trial end points: "RECIST"ing a step backwards. Clin Cancer Res 11:5223-5232, 2005
33. de Bono JS, Bellmunt J, Droz JP, et al: An open label, phase II, multicenter, study to evaluate the efficacy and safety of pertuzumab (P) in chemotherapy naive patients (pts) with hormone refractory prostate cancer (HRPC). J Clin Oncol 23:405s, 2005 (suppl; abstr 4609)
34. Denmeade SR, Sokoll LJ, Dalrymple S, et al: Dissociation between androgen responsiveness for malignant growth vs. expression of prostate specific differentiation markers PSA, hK2, and PSMA in human prostate cancer models. Prostate 54:249-257, 2003
35. Shi Y, Brands FH, Chatterjee S, et al: HER-2/neu expression in prostate cancer: High level of expression associated with exposure to hormone therapy and androgen independent disease. J Urol 166:1514-1519, 2001
36. Osman I, Scher HI, Drobnjak M, et al: HER-2/neu (p185neu) protein expression in the natural or treated history of prostate cancer. Clin Cancer Res 7:2643-2647, 2001
37. Oh WK, Manola J, Babcic V, et al: Response to second-line chemotherapy in patients with hormone refractory prostate cancer receiving two sequences of mitoxantrone and taxanes. Urology 67:1235-1240, 2006
38. Michels J, Montemurro T, Kollmannsberger C, et al: First- and second-line chemotherapy with docetaxel or mitoxantrone in patients with hormone-refractory prostate cancer (HRPC): Does sequence matter? J Clin Oncol 23:404s, 2005 (suppl; abstr 4611)